{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:59:27Z","timestamp":1774969167951,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22083-2","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:22:48Z","timestamp":1761913368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhixing","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanfa","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"22083_CR1","doi-asserted-by":"publisher","unstructured":"Roky, A. H. et al. Overview of skin cancer types and prevalence rates across continents. Cancer Pathog Ther. S2949713224000582 https:\/\/doi.org\/10.1016\/j.cpt.2024.08.002 (2024).","DOI":"10.1016\/j.cpt.2024.08.002"},{"key":"22083_CR2","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/1078-0432.CCR-09-2570","volume":"16","author":"I Caro","year":"2010","unstructured":"Caro, I. & Low, J. A. The role of the Hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin. Cancer Res. : Off J. Am. Assoc. Cancer Res. 16, 3335\u20133339 (2010).","journal-title":"Clin. Cancer Res. : Off J. Am. Assoc. Cancer Res."},{"key":"22083_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing, J. et al. Hedgehog signaling in tissue homeostasis, cancers and targeted therapies. Signal. Transduct. Target. Ther. 8, 1\u201333 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"22083_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda, A. M. et al. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J. Basic. Med. Sci. 18, 8\u201320 (2018).","journal-title":"Bosn J. Basic. Med. Sci."},{"key":"22083_CR5","doi-asserted-by":"crossref","unstructured":"Ma, C. et al. Molecular mechanisms involving the Sonic Hedgehog pathway in lung cancer therapy: recent advances. Front Oncol 12, 729088 (2022).","DOI":"10.3389\/fonc.2022.729088"},{"key":"22083_CR6","doi-asserted-by":"publisher","first-page":"13979","DOI":"10.3390\/ijms140713979","volume":"14","author":"A Gonnissen","year":"2013","unstructured":"Gonnissen, A., Isebaert, S. & Haustermans, K. Hedgehog signaling in prostate cancer and its therapeutic implication. Int. J. Mol. Sci. 14, 13979\u201314007 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"22083_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cells8020153","volume":"8","author":"D Girardi","year":"2019","unstructured":"Girardi, D., Barrichello, A., Fernandes, G. & Pereira, A. Targeting the Hedgehog pathway in cancer: current evidence and future perspectives. Cells 8, 153 (2019).","journal-title":"Cells"},{"key":"22083_CR8","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1242\/dev.00653","volume":"130","author":"H Kawahira","year":"2003","unstructured":"Kawahira, H. et al. Combined activities of Hedgehog signaling inhibitors regulate pancreas development. Development 130, 4871\u20134879 (2003).","journal-title":"Development"},{"key":"22083_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.36849\/JDD.5657","volume":"20","author":"M Migden","year":"2021","unstructured":"Migden, M., Farberg, A., Dummer, R., Squittieri, N. & Hanke, C. W. A review of Hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma. J. Drugs Dermatol. 20, 156\u2013165 (2021).","journal-title":"J. Drugs Dermatol."},{"key":"22083_CR10","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy, K. J. et al. FDA approval summary: Glasdegib for newly diagnosed acute myeloid leukemia. Clin. Cancer Res. 25, 6021\u20136025 (2019).","journal-title":"Clin. Cancer Res."},{"key":"22083_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers8020022","volume":"8","author":"T Rimkus","year":"2016","unstructured":"Rimkus, T., Carpenter, R., Qasem, S., Chan, M. & Lo, H. W. Targeting the Sonic Hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers 8, 22 (2016).","journal-title":"Cancers"},{"key":"22083_CR12","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","volume":"19","author":"KD Robarge","year":"2009","unstructured":"Robarge, K. D. et al. GDC-0449\u2014a potent inhibitor of the Hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576\u20135581 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"22083_CR13","doi-asserted-by":"crossref","unstructured":"Basset-S\u00e9guin, N. et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur. J. Cancer (Oxf. Engl.:) 86, 334\u2013348 (2017).) 86, 334\u2013348 (2017). (1990).","DOI":"10.1016\/j.ejca.2017.08.022"},{"key":"22083_CR14","unstructured":"FDA. Labeling-package insert of vismodegib (Erivedge). (2023)."},{"key":"22083_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/OTT.S130910","volume":"10","author":"S Jain","year":"2017","unstructured":"Jain, S., Song, R. & Xie, J. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. OncoTargets Ther. 10, 1645\u20131653 (2017).","journal-title":"OncoTargets Ther."},{"key":"22083_CR16","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-16-2051","volume":"23","author":"D Casey","year":"2017","unstructured":"Casey, D. et al. FDA approval summary: sonidegib for locally advanced basal cell carcinoma. Clin. Cancer Res. 23, 2377\u20132381 (2017).","journal-title":"Clin. Cancer Res."},{"key":"22083_CR17","unstructured":"FDA. Labeling-package insert of sonidegib (Odomzo). (2023)."},{"key":"22083_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/ijd.14780","volume":"59","author":"R Cozzani","year":"2020","unstructured":"Cozzani, R. et al. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. Int. J. Dermatol. 59, 627\u2013632 (2020).","journal-title":"Int. J. Dermatol."},{"key":"22083_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic, A. et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 17, 332 (2017).","journal-title":"BMC Cancer"},{"key":"22083_CR20","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br. J. Dermatol. 182, 1369\u20131378 (2020).","journal-title":"Br. J. Dermatol."},{"key":"22083_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no, B. et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 18, 404\u2013412 (2017).","journal-title":"Lancet Oncol."},{"key":"22083_CR22","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen, C., Wu, B., Zhang, C. & Xu, T. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int. Immunopharmacol. 95, 107498 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"22083_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli, M. et al. Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 45, 891\u2013908 (2022).","journal-title":"Drug Saf."},{"key":"22083_CR24","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.2340\/00015555-3495","volume":"100","author":"N Basset-Seguin","year":"2020","unstructured":"Basset-Seguin, N. & Herms, F. Update on the management of basal cell carcinoma. Acta Derm Venereol. 100, 5750 (2020).","journal-title":"Acta Derm Venereol."},{"key":"22083_CR25","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/jdv.16230","volume":"34","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J. Eur. Acad. Dermatol. Venereol. 34, 1944\u20131956 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"22083_CR26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaad.2017.11.045","volume":"78","author":"E Girard","year":"2018","unstructured":"Girard, E. et al. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: a prospective study in 30 patients. J. Am. Acad. Dermatol. 78, 1213\u20131216e2 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"22083_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2012.09.021","volume":"151","author":"R Teperino","year":"2012","unstructured":"Teperino, R. et al. Hedgehog partial agonism drives warburg-like metabolism in muscle and brown fat. Cell 151, 414\u2013426 (2012).","journal-title":"Cell"},{"key":"22083_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamadermatol.2015.1937","volume":"151","author":"MS Ally","year":"2015","unstructured":"Ally, M. S. et al. Effect of calcium channel Blockade on vismodegib-induced muscle cramps. JAMA dermatol. 151, 1132\u20131134 (2015).","journal-title":"JAMA dermatol."},{"key":"22083_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-020-00464-x","volume":"11","author":"N Teh","year":"2021","unstructured":"Teh, N. & Leow, L. J. The role of actin in muscle spasms in a case series of patients with advanced basal cell carcinoma treated with a Hedgehog pathway inhibitor. Dermatol. Ther. 11, 293\u2013299 (2021).","journal-title":"Dermatol. Ther."},{"key":"22083_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","volume":"75","author":"R Dummer","year":"2016","unstructured":"Dummer, R. et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J. Am. Acad. Dermatol. 75, 113\u2013125e5 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"22083_CR31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/bjd.15738","volume":"177","author":"C Dessinioti","year":"2017","unstructured":"Dessinioti, C., Antoniou, C. & Stratigos, A. J. From basal cell carcinoma morphogenesis to the alopecia induced by Hedgehog inhibitors: connecting the Dots. Br. J. Dermatol. 177, 1485\u20131494 (2017).","journal-title":"Br. J. Dermatol."},{"key":"22083_CR32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000510121","volume":"6","author":"M Cantelli","year":"2020","unstructured":"Cantelli, M. et al. Vismodegib-induced alopecia: trichoscopic and confocal microscopy evaluation. Skin. Appendage Disord. 6, 384\u2013388 (2020).","journal-title":"Skin. Appendage Disord"},{"key":"22083_CR33","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1152\/jn.00822.2014","volume":"113","author":"A Kumari","year":"2015","unstructured":"Kumari, A. et al. Hedgehog pathway Blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J. Neurophysiol. 113, 1034\u20131040 (2015).","journal-title":"J. Neurophysiol."},{"key":"22083_CR34","doi-asserted-by":"publisher","first-page":"E10369","DOI":"10.1073\/pnas.1712881114","volume":"114","author":"A Kumari","year":"2017","unstructured":"Kumari, A. et al. Recovery of taste organs and sensory function after severe loss from hedgehog\/smoothened Inhibition with cancer drug sonidegib. Proc. Natl. Acad. Sci. U S A. 114, E10369\u2013E10378 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"22083_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jdcr.2020.11.014","volume":"7","author":"J Yoon","year":"2020","unstructured":"Yoon, J. Vismodegib dose reduction effective when combined with Itraconazole for the treatment of advanced basal cell carcinoma. JAAD Case Rep. 7, 107\u2013109 (2020).","journal-title":"JAAD Case Rep."},{"key":"22083_CR36","first-page":"1689","volume":"24","author":"M Le Moigne","year":"2016","unstructured":"Le Moigne, M. et al. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 24, 1689\u20131695 (2016).","journal-title":"Support Care Cancer"},{"key":"22083_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1083\/jcb.200805155","volume":"184","author":"DS Wall","year":"2009","unstructured":"Wall, D. S. et al. Progenitor cell proliferation in the retina is dependent on notch-independent Sonic hedgehog\/Hes1 activity. J. Cell. Biol. 184, 101\u2013112 (2009).","journal-title":"J. Cell. Biol."},{"key":"22083_CR38","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1523\/JNEUROSCI.0312-08.2008","volume":"28","author":"EC Driver","year":"2008","unstructured":"Driver, E. C. et al. Hedgehog signaling regulates sensory cell formation and auditory function in mice and humans. J. Neurosci. : Off J. Soc. Neurosci. 28, 7350\u20137358 (2008).","journal-title":"J. Neurosci. : Off J. Soc. Neurosci."},{"key":"22083_CR39","doi-asserted-by":"crossref","unstructured":"Maurya, D. K., Bohm, S. & Alenius, M. Hedgehog signaling regulates ciliary localization of mouse odorant receptors. Proc. Natl. Acad. Sci. U. S. A. 114, E9386\u2013E9394 (2017).","DOI":"10.1073\/pnas.1708321114"},{"key":"22083_CR40","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1158\/0008-5472.CAN-14-2999-T","volume":"75","author":"X Zhao","year":"2015","unstructured":"Zhao, X. et al. RAS\/MAPK activation drives resistance to Smo inhibition, metastasis, and tumor evolution in Shh pathway-dependent tumors. Cancer Res. 75, 3623\u20133635 (2015).","journal-title":"Cancer Res."},{"key":"22083_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cells8040375","volume":"8","author":"NA Riobo-Del Galdo","year":"2019","unstructured":"Riobo-Del Galdo, N. A., Lara Montero, \u00c1. & Wertheimer, E. V. Role of Hedgehog signaling in breast cancer: pathogenesis and therapeutics. Cells 8, 375 (2019).","journal-title":"Cells"},{"key":"22083_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/bjc.2017.116","volume":"116","author":"C Di Mauro","year":"2017","unstructured":"Di Mauro, C. et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br. J. Cancer. 116, 1425\u20131435 (2017).","journal-title":"Br. J. Cancer"},{"key":"22083_CR43","doi-asserted-by":"publisher","first-page":"vi87","DOI":"10.1093\/annonc\/mdw365.60","volume":"27","author":"M Mart\u00edn","year":"2016","unstructured":"Mart\u00edn, M. et al. A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM\/2012-12 (EDALINE study). Ann. Oncol. 27, vi87 (2016).","journal-title":"Ann. Oncol."},{"key":"22083_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s10637-018-0614-9","volume":"37","author":"M Ruiz-Borrego","year":"2019","unstructured":"Ruiz-Borrego, M. et al. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM\/2012\u201312 (EDALINE) study. Invest. New. Drugs. 37, 98\u2013108 (2019).","journal-title":"Invest. New. Drugs"},{"key":"22083_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00439-018-1918-8","volume":"138","author":"F Cavodeassi","year":"2019","unstructured":"Cavodeassi, F., Creuzet, S. & Etchevers, H. C. The Hedgehog pathway and ocular developmental anomalies. Hum. Genet. 138, 917\u2013936 (2019).","journal-title":"Hum. Genet."},{"key":"22083_CR46","first-page":"2610","volume":"142","author":"L Todd","year":"2015","unstructured":"Todd, L. & Fischer, A. J. Hedgehog signaling stimulates the formation of proliferating m\u00fcller glia-derived progenitor cells in the chick retina. Dev. (camb Engl). 142, 2610\u20132622 (2015).","journal-title":"Dev. (camb Engl)"},{"key":"22083_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1167\/iovs.62.2.33","volume":"62","author":"JY Qu","year":"2021","unstructured":"Qu, J. Y., Xiao, Y. T., Zhang, Y. Y., Xie, H. T. & Zhang, M. C. Hedgehog signaling pathway regulates the proliferation and differentiation of rat meibomian gland epithelial cells. Invest. Ophthalmol. Visual Sci. 62, 33 (2021).","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"22083_CR48","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2147\/DDDT.S149594","volume":"12","author":"M Liu","year":"2018","unstructured":"Liu, M., Chen, X., Liu, H. & Di, Y. Expression and significance of the Hedgehog signal transduction pathway in oxygen-induced retinal neovascularization in mice. Drug Des. Dev. Ther. 12, 1337\u20131346 (2018).","journal-title":"Drug Des. Dev. Ther."},{"key":"22083_CR49","doi-asserted-by":"publisher","first-page":"1408135","DOI":"10.3389\/fphar.2024.1408135","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang, K., Wang, M., Li, W. & Wang, X. A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system. Front. Pharmacol. 15, 1408135 (2024).","journal-title":"Front. Pharmacol."},{"key":"22083_CR50","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu, S., Hu, W., Chen, M., Xiao, X. & Liu, R. A real-world pharmacovigilance study of FDA adverse event reporting system events for lutetium-177-PSMA-617. Sci. Rep. 14, 25712 (2024).","journal-title":"Sci. Rep."},{"key":"22083_CR51","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front. Pharmacol. 13, 862508 (2022).","journal-title":"Front. Pharmacol."},{"key":"22083_CR52","doi-asserted-by":"publisher","first-page":"990241","DOI":"10.3389\/fphar.2022.990241","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database. Front. Pharmacol. 13, 990241 (2022).","journal-title":"Front. Pharmacol."},{"key":"22083_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229 (2024).","journal-title":"J. Affect. Disord"},{"key":"22083_CR54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"22083_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S., Hosomi, K., Yokoyama, S. & Takada, M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45, 65\u201371 (2020).","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22083-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:03:08Z","timestamp":1761915788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22083-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22083"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22083-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. The FAERS is a public database that contains reports of adverse events voluntarily submitted to FDA. The data used in our study are derived from this database, hence ethical approval and patient informed consent are not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"38170"}}